Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

Michael B. Atkins, MD
Published: Thursday, Dec 07, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

For the past 20 years, there have been constant debate over what adjuvant treatments should be used in which patients with melanoma, says Atkins. But none of the available treatments were effective of tolerable enough to justify their widespread use, Atkins add.

Recently, a trial looking at vemurafenib (Zelboraf), the COMBI-d study of dabrafenib (Tafinlar) plus trametinib (Mekinist), and a trial comparing nivolumab (Opdivo) with high-dose ipilimumab (Yervoy), showed promise across varying stages of disease.
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

For the past 20 years, there have been constant debate over what adjuvant treatments should be used in which patients with melanoma, says Atkins. But none of the available treatments were effective of tolerable enough to justify their widespread use, Atkins add.

Recently, a trial looking at vemurafenib (Zelboraf), the COMBI-d study of dabrafenib (Tafinlar) plus trametinib (Mekinist), and a trial comparing nivolumab (Opdivo) with high-dose ipilimumab (Yervoy), showed promise across varying stages of disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x